Exosome Diagnostics to Present a Novel Atlas of Exosomal mRNA and Long non-coding RNA Across Biofluids at American Society of Exosomes and Microvesicles Annual Meeting

Waltham, MA, Oct. 11, 2017 (GLOBE NEWSWIRE) —

Exosome Diagnostics, Inc. will be presenting the company’s cutting edge long-RNAseq platform at this year’s American Society of Exosomes and Microvesicles (ASEMV) on October 12th in Pacific Beach, CA. Exosome Dx will showcase the capabilities of the platform by creating the first profiles of exosomal mRNA and long non-coding RNA in four biofluids; plasma, serum, CSF, and urine.  While the majority of the field are focused on exosomal small-RNAs, Exosome Dx will show that long-RNAs are consistently detected in these diverse biofluids and that they represent a much broader and more relevant diagnostic domain than smallRNAs.  Finally, Exosome Dx present initial findings from its’ EDDE platform that is capable of selectively enriching or depleting sub-populations of exosomes prior to long-RNA sequencing

“This study highlights the broad applications of our exosome platform and an atlas of the exosome transcriptome. We will also present data on our EDDE enrichment/depletion platform that is critical for some biomarker applications. Isolation of total plasma RNA often add too much noise to see a critical biomarker signature and we have shown how EDDE can address this problem by only analysing the relevant exosome fraction.”  Stated Johan Skog, founding scientist and Chief Scientific Officer of Exosome Diagnostics.

”Exosome has developed a robust platform for detection of a novel source of biomarkers for diagnostic and companion diagnostic purposes,” stated John Boyce, President and CEO of Exosome Diagnostics.  “The ability to deplete or enrich sub-populations of exosomes significantly improves the signal to noise allowing for low allele frequency detection and will also allow the company to detect tissue derived proteins, within blood, that were previously undetectable from certain tissue types, such as brain,” Boyce continued.

About ASEMV

ASEMV was founded in 2012 to advance the field of exosomes and microvesicle research. Each year they host the foremost thought leaders from the US and across the world to share research in one of the fastest growing fields of personalized medicine.

About Exosome Diagnostics

Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution™, and point of care instrument for protein capture and analysis, ShahkyTM, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are diagnosed, treated and monitored. Visit www.exosomedx.com to learn more.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e7b5aa23-628a-4299-a28b-467266a89610

CONTACT: Dan Baughman
Exosome Diagnostics
248 613 2247
dbaughman@exosomedx.com

Left Menu Icon
Right Menu Icon